BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32900667)

  • 1. De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial?
    Montasser IF; Ibrahim AA; Farid HM; Al Balakosy AM
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101517. PubMed ID: 32900667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals.
    El-Kassas M; Sayed H; Omran D; Eldahrouty AH; Elbaz T; Kamal E
    Asian Pac J Cancer Prev; 2023 Feb; 24(2):597-605. PubMed ID: 36853310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs).
    Ghanem S; El Gedawy G; Yehia S; Bedair H; Awad S; Abdel-Razek W; Elhelbawy M; El-Sabaawy D; Elfert AY
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):149-155. PubMed ID: 36708563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study.
    Omran M; Fouda M; Abdelwahab AO; Nabeel MM; Abdelaziz AO; Omran D; Shousha HI
    Eur J Gastroenterol Hepatol; 2022 Feb; 34(2):220-226. PubMed ID: 33079785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
    Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
    J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
    Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
    Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
    Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    Aliment Pharmacol Ther; 2018 Jan; 47(1):104-113. PubMed ID: 29035002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals.
    Faillaci F; Marzi L; Critelli R; Milosa F; Schepis F; Turola E; Andreani S; Vandelli G; Bernabucci V; Lei B; D'Ambrosio F; Bristot L; Cavalletto L; Chemello L; Sighinolfi P; Manni P; Maiorana A; Caporali C; Bianchini M; Marsico M; Turco L; de Maria N; Del Buono M; Todesca P; di Lena L; Romagnoli D; Magistri P; di Benedetto F; Bruno S; Taliani G; Giannelli G; Martinez-Chantar ML; Villa E
    Hepatology; 2018 Sep; 68(3):1010-1024. PubMed ID: 29604220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    Sangiovanni A; Alimenti E; Gattai R; Filomia R; Parente E; Valenti L; Marzi L; Pellegatta G; Borgia G; Gambato M; Terreni N; Serio I; Belli L; Oliveri F; Maimone S; Brunacci M; D'Ambrosio R; Forzenigo LV; Russo FP; Rumi M; Barone M; Fracanzani AL; Raimondo G; Giannini EG; Brunetto MR; Villa E; Biganzoli E; Colombo M; Lampertico P
    J Hepatol; 2020 Sep; 73(3):593-602. PubMed ID: 32243959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus.
    Guardigni V; Toschi A; Badia L; Rosselli Del Turco E; Salsi E; Cristini F; Sighinolfi L; Fabbri G; Massari M; Cuomo G; Viale P; Verucchi G;
    AIDS; 2021 Oct; 35(12):1967-1972. PubMed ID: 34101631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients.
    Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Hashem MB; Hassan EM; Salah A; Omran DA; Elbaz TM
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):75-79. PubMed ID: 30199473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.
    Cabibbo G; Petta S; Calvaruso V; Cacciola I; Cannavò MR; Madonia S; Distefano M; Larocca L; Prestileo T; Tinè F; Bertino G; Giannitrapani L; Benanti F; Licata A; Scalisi I; Mazzola G; Cartabellotta F; Alessi N; Barbàra M; Russello M; Scifo G; Squadrito G; Raimondo G; Craxì A; Di Marco V; Cammà C;
    Aliment Pharmacol Ther; 2017 Oct; 46(7):688-695. PubMed ID: 28791711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation Between Vascular Endothelial Growth Factor and Long-Term Occurrence of HCV-Related Hepatocellular Carcinoma After Treatment with Direct-Acting Antivirals.
    Ramadan HK; Meghezel EM; Abdel-Malek MO; Askar AA; Hetta HF; Mahmoud AA; Abdel-Aal AM
    Cancer Invest; 2021 Sep; 39(8):653-660. PubMed ID: 34224250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study.
    Ramadan HK; Badr G; Ramadan NK; Sayed A
    Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33524139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular Carcinoma Occurrence/Recurrence after Direct-Acting Antivirals for Hepatitis C in Egyptian Cohort: Single-Center Experience.
    Lashen SA; Shamseya MM; Madkour MA
    Dig Dis; 2019; 37(6):488-497. PubMed ID: 31216532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.